How to reconstitute Kisspeptin-10: mixing and storage
A short-acting experimental peptide that triggers reproductive hormone release.
Also called: KP-10, KP10, Kisspeptin 112-121, Metastin 45-54, NSC 741805.
Reproductive axis peptides · KISS1 receptor agonist.
Comes as: Community: freeze-dried powder vials, Research: controlled IV solution or SC pump infusion, FDA review: compounded injections and troches, without an approved label.
Mixed with: Community reports describe bacteriostatic water; clinical studies used controlled saline-based preparations. These are separate practices..
Common vial sizes: 10 mg. Common water amounts: 1, 2, 3 mL.
- Forum reports describe 10 mg vials with 1, 2 or 3 mL water; these are reported choices, not validated formulations.
- Gelling was reported after 10 mg with 2 mL bacteriostatic water. Do not treat a changed or cloudy product as a usable solution.
- No evidence supports rescuing a gelled vial by adding acid at home.
- Clinical study handling and vial checks cannot be transferred to an unidentified online powder.
Before mixing: Community posters describe freezing dry vials. No validated shelf life was found for an unidentified vial; formulation and packaging matter.
After mixing: Community reports use refrigeration. No validated home-use expiry or sterility period was found; a clear vial is not proof of sterility.
Related to Kisspeptin-10
- Gonadorelin: A short-acting fertility hormone used in tests and specialist pump therapy.
- hCG: A fertility hormone with limited testosterone add-on evidence and no proven weight-loss benefit.
- Bremelanotide: An as-needed injection for low libido before menopause; nausea is common.
- Hexarelin: A peptide that releases growth hormone; repeated use can weaken the response.
Sources
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Concerns regarding the public health risks associated with unapproved peptide products, Therapeutic Goods Administration and Chief Medical Officer · Therapeutic Goods Administration · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Supply unlicensed medicinal products (specials), MHRA · 2025
- October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee
- October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting
- Unauthorized injectable peptide drugs seized from Optimum Wellness Centre in Calgary, Alberta may pose serious health risks, Health Canada
- Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men., Yeung AC et al. · European journal of endocrinology · 2026
- Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men., Naveed A et al. · Hormones (Athens, Greece) · 2026
- Intravenous kisspeptin 112-121 bolus does not acutely impact circulating vasopressin in humans., Galbiati F et al. · Journal of neuroendocrinology · 2026
- Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans., Mills EG et al. · EBioMedicine · 2025
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.